Karus Therapeutics Announces Strategic Collaboration with The University of Texas MD Anderson Cancer Center

Oxford, UK, 10 December 2015 – Karus Therapeutics (‘Karus’), a leader in the development of innovative medicines with breakthrough potential in the treatment of hematological cancers and solid tumor immunotherapy, today announced that it has entered into a strategic pre-clinical and clinical collaboration with The University of Texas MD Anderson Cancer Center. The collaboration will […]

Karus Therapeutics presenting at the 4th Annual Cancer BioPartnering & Investment Forum

Oxford, UK, 7 December 2015 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced that Simon Kerry, Karus Therapeutics’ CEO will be giving a company presentation at the 4thAnnual Cancer BioPartnering & Investment Forum, New York, USA on the 24th February 2016. For more information on […]

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity (Orlando)

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity. Alexander A., Bone E.A., Cecil A.R.L., Colman L., Dow J., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Ward P., Whale A., Shuttleworth S.J. 57th ASH Annual Meeting and Exposition, Orlando, […]

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity (Brussels)

Design and Development of a Novel PI3K-p110ß/d Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity. Alexander R., Bone E.A., Cecil A.R.L., Colman L., Dow J., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Ward P., Whale A., Shuttleworth S.J. EORTC-NCI-EMA-AACR Conference on Innovation and Biomarkers in […]

Karus Therapeutics presenting at the 8th Annual Biotech Showcase 2016

Oxford, UK, 30th November 2015 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced that Simon Kerry, Karus Therapeutics’ CEO will be giving a company presentation at the Biotech Showcase, San Francisco, USA, 11th-13th January 2016. For more information on Karus’s presentations or for media enquiries, […]

Karus Therapeutics presenting at the 57th ASH Annual Meeting

Oxford, UK, 26th November 2015 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced that it will be giving a poster presentation at the 57th ASH Annual Meeting, Orlando, USA. The poster presentation is entitled “Design and Development of a Novel Orally-Active, PI3K-p110Beta/Delta Inhibitor with Combined […]

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity (Boston)

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity. Whale A.D., Alexander R., Bone E.A., Cecil A.R.L., Colman L., Dow J., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Shuttleworth S.J. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, […]

Design and Development of a Novel HDAC6-Selective Inhibitor, KA2507, for Hematological Cancer Treatment and Solid Tumor Immunotherapy (Boston)

Design and Development of a Novel HDAC6-Selective Inhibitor, KA2507, for Hematological Cancer Treatment and Solid Tumor Immunotherapy. Whale A.D., Alexander R., Bone E.A., Cecil A.R.L., Colman L., Dow J., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Shuttleworth S.J. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, […]

Karus Therapeutics presenting at the EORTC-NCI-EMA-AACR Innovation and Biomarkers in Cancer Drug Development

Oxford, UK, 2 November 2015 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced that it will be giving a poster presentation at the EORTC-NCI-EMA-AACR Innovation and Biomarkers in Cancer Drug Development, Brussels, Belgium. The conference will take place in 2016. The poster presentation is entitled […]

Karus Therapeutics presenting AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oxford, UK, 4 October 2015 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced that it will be giving two poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 5-9 November 2015, Boston, USA. The poster presentations are as follow: Abstract B115 […]